Part D Plans Offer Broad Drug Access For Dual Eligibles, With Some Exceptions - OIG Study
This article was originally published in The Pink Sheet Daily
Vytorin, Lunesta and Avapro are among eight drugs that are covered by fewer than 75% of plans available to beneficiaries eligible for both Medicare and Medicaid.
You may also be interested in...
Reimbursement Briefs: 340B, Exchange Plan Cost-Sharing, Part D Dual Eligibles
HRSA’s Office of Pharmacy Affairs adds a new branch to oversee compliance in the 340B drug discount program; a PhRMA-funded study finds high coinsurance for drugs used by enrollees in many state exchange plans; OIG says Part D plans are covering a high percentage of drugs used by Medicare/Medicaid dual eligibles.
Propoxyphene Marketing Halted By FDAAA-Required QT Safety Study
The opioid, marketed under the Darvon and Darvocet brands and in generic form, has the ignominious distinction of being the first drug pulled from the market based on results of a post-marketing safety study required under the 2007 law.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.